-
公开(公告)号:US08518911B2
公开(公告)日:2013-08-27
申请号:US13057510
申请日:2009-07-27
申请人: Jason D. Katz , Sandra L. Knowles , James P. Jewell , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
发明人: Jason D. Katz , Sandra L. Knowles , James P. Jewell , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
IPC分类号: A61K31/675 , A61K31/437 , A61K31/496 , A61K31/397
CPC分类号: A61K31/425 , C07D417/04 , C07D417/14
摘要: The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括选择性抑制微管亲和调节激酶(MARK)的吡唑并[1,5-a]吡啶衍生物,因此可用于治疗或预防阿尔茨海默氏病。 还包括药物组合物和使用方法。
-
公开(公告)号:US20110195933A1
公开(公告)日:2011-08-11
申请号:US13057510
申请日:2009-07-27
申请人: Jason D. Katz , Sandra L. Knowles , James P. Jewell , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
发明人: Jason D. Katz , Sandra L. Knowles , James P. Jewell , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
IPC分类号: A61K31/675 , C07D471/04 , A61K31/437 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D471/10 , A61K31/438 , A61K31/397 , C07F9/576 , A61K31/5513 , A61P25/28
CPC分类号: A61K31/425 , C07D417/04 , C07D417/14
摘要: The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括选择性抑制微管亲和调节激酶(MARK)的吡唑并[1,5-a]吡啶衍生物,因此可用于治疗或预防阿尔茨海默氏病。 还包括药物组合物和使用方法。
-
公开(公告)号:US20130210838A1
公开(公告)日:2013-08-15
申请号:US13521382
申请日:2011-01-11
申请人: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
发明人: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
IPC分类号: C07D487/04
CPC分类号: C07D487/04
摘要: The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括选择性抑制微管亲和调节激酶(MARK)的吡唑并[1,5-a]嘧啶衍生物,因此可用于治疗或预防阿尔茨海默氏病。 还包括药物组合物和使用方法。
-
公开(公告)号:US08946237B2
公开(公告)日:2015-02-03
申请号:US13521382
申请日:2011-01-11
申请人: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
发明人: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
IPC分类号: A01N43/90 , A61K31/519 , C07D487/00 , C07D487/04
CPC分类号: C07D487/04
摘要: The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括选择性抑制微管亲和调节激酶(MARK)的吡唑并[1,5-a]嘧啶衍生物,因此可用于治疗或预防阿尔茨海默氏病。 还包括药物组合物和使用方法。
-
公开(公告)号:US20100305091A1
公开(公告)日:2010-12-02
申请号:US12669843
申请日:2008-07-16
IPC分类号: A61K31/519 , C07D487/04 , A61K31/5377 , C07D471/08 , A61P25/28
CPC分类号: C07D519/00 , C07D487/04
摘要: Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.
摘要翻译: 下式(I)的化合物是微管亲和调节激酶的抑制剂,因此可用于治疗与tau的过度磷酸化有关的神经变性疾病。
-
公开(公告)号:US08461162B2
公开(公告)日:2013-06-11
申请号:US12669843
申请日:2008-07-16
IPC分类号: A01N43/90 , A61K31/519 , C07D487/00
CPC分类号: C07D519/00 , C07D487/04
摘要: Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.
摘要翻译: 下式(I)的化合物是微管亲和调节激酶的抑制剂,因此可用于治疗与tau的过度磷酸化有关的神经变性疾病。
-
公开(公告)号:US20090209566A1
公开(公告)日:2009-08-20
申请号:US12085396
申请日:2006-11-17
申请人: Scott C. Berk , Joshua Close , Christopher Hamblett , Richard W. Heidebrecht , Solomon D. Kattar , Laura T. Kliman , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Paul Tempest , Anna A. Zabierek
发明人: Scott C. Berk , Joshua Close , Christopher Hamblett , Richard W. Heidebrecht , Solomon D. Kattar , Laura T. Kliman , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Paul Tempest , Anna A. Zabierek
IPC分类号: A61K31/438 , C07D471/10 , C07D491/107 , C07D498/10 , C07D487/10 , A61K31/4439 , A61K31/506 , A61P35/00
CPC分类号: C07D471/10 , C07D487/10 , C07D491/10 , C07D491/107 , C07D498/10
摘要: The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR12, NR1a, C(O) and O; E is selected from a bond, CR12, NR1a, C(O) and O; wherein at least one of A, B, D or E is CR12; and provided that when A is O, then E is not O; G is CR12; R is selected from NH2 and OH; These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing termin differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
摘要翻译: 本发明涉及由下列结构式表示的新一类取代的螺环化合物:其中A,B和D独立地选自CR12,NR1a,C(O)和O; E选自键,CR12,NR1a,C(O)和O; 其中A,B,D或E中的至少一个为CR 12; 并且条件是当A为O时,则E不为O; G是CR12; R选自NH 2和OH; 这些化合物可以抑制组蛋白脱乙酰酶,适用于选择性诱导终末分化,阻止肿瘤细胞的细胞生长和/或凋亡,从而抑制这些细胞的增殖。 因此,本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。 本发明的化合物还可用于预防和治疗TRX介导的疾病,例如自身免疫性,过敏性和炎性疾病,以及预防和/或治疗中枢神经系统疾病(CNS),例如 神经退行性疾病 本发明进一步提供包含本发明化合物和易于遵循的这些药物组合物的安全给药方案的药物组合物,并且其在体内导致治疗有效量的这些化合物。
-
公开(公告)号:US20090082308A1
公开(公告)日:2009-03-26
申请号:US11918913
申请日:2006-04-14
申请人: Jed Lee Hubbs , Dawn M. Mampreian , Joey L. Methot , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , David L. Sloman , Matthew G. Stanton , Kevin J. Wilson , David J. Witter
发明人: Jed Lee Hubbs , Dawn M. Mampreian , Joey L. Methot , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , David L. Sloman , Matthew G. Stanton , Kevin J. Wilson , David J. Witter
IPC分类号: A61K31/695 , C07D333/56 , A61K31/381 , C07D409/12 , A61K31/4709 , C07D409/10 , A61K31/4025 , C07D409/06 , A61K31/496 , C07D413/12 , A61P25/00 , A61P35/00 , A61K31/4155 , A61K31/506 , C07F7/08 , A61K31/5377 , C07D409/14 , A61K31/4178 , A61K31/404 , A61K31/4436 , A61K31/4245 , A61K31/4192
CPC分类号: C07D333/70 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/14
摘要: The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.
摘要翻译: 本发明涉及一类新型的苯并噻吩酰胺衍生物。 异羟肟酸化合物可用于治疗癌症。 苯并噻吩酰胺化合物也可以抑制组蛋白脱乙酰酶,适用于选择性诱导末端分化,阻止肿瘤细胞的细胞生长和/或凋亡,从而抑制这些细胞的增殖。 因此,本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。 本发明的化合物还可用于预防和治疗TRX介导的疾病,例如自身免疫性,过敏性和炎性疾病,以及预防和/或治疗中枢神经系统疾病(CNS),例如 神经退行性疾病 本发明进一步提供包含异羟肟酸衍生物和这些药物组合物的安全投药方案的药物组合物,它们易于遵循,并且其在体内导致治疗有效量的异羟肟酸衍生物。
-
公开(公告)号:US07834026B2
公开(公告)日:2010-11-16
申请号:US12085396
申请日:2006-11-17
申请人: Scott C. Berk , Joshua Close , Christopher Hamblett , Richard W. Heidebrecht , Solomon D. Kattar , Laura T. Kliman , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Paul Tempest , Anna A. Zabierek
发明人: Scott C. Berk , Joshua Close , Christopher Hamblett , Richard W. Heidebrecht , Solomon D. Kattar , Laura T. Kliman , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Paul Tempest , Anna A. Zabierek
IPC分类号: A01N43/42 , A01N43/12 , A01N43/26 , A61K31/44 , A61K31/34 , A61K31/335 , C07D237/00 , C07D239/00 , C07D241/00 , C07D491/10 , C07D491/20 , C07D495/10 , C07D495/20 , C07D497/10 , C07D497/20 , C07D311/96 , C07D313/06 , C07D313/20 , C07D315/00
CPC分类号: C07D471/10 , C07D487/10 , C07D491/10 , C07D491/107 , C07D498/10
摘要: The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR12, NR1a, C(O) and O; E is selected from a bond, CR12, NR1a, C(O) and O; wherein at least one of A, B, D or E is CR12; and provided that when A is O, then E is not O; G is CR12; R is selected from NH2 and OH; These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing termin differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
摘要翻译: 本发明涉及由下列结构式表示的新一类取代的螺环化合物:其中A,B和D独立地选自CR12,NR1a,C(O)和O; E选自键,CR12,NR1a,C(O)和O; 其中A,B,D或E中的至少一个为CR 12; 并且条件是当A为O时,则E不为O; G是CR12; R选自NH 2和OH; 这些化合物可以抑制组蛋白脱乙酰酶,适用于选择性诱导终末分化,阻止肿瘤细胞的细胞生长和/或凋亡,从而抑制这些细胞的增殖。 因此,本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。 本发明的化合物还可用于预防和治疗TRX介导的疾病,例如自身免疫性,过敏性和炎性疾病,以及预防和/或治疗中枢神经系统(CNS)的疾病,例如 神经退行性疾病 本发明进一步提供包含本发明化合物和易于遵循的这些药物组合物的安全给药方案的药物组合物,并且其在体内产生治疗有效量的这些化合物。
-
公开(公告)号:US20090105264A1
公开(公告)日:2009-04-23
申请号:US12084272
申请日:2006-10-30
申请人: Christopher Hamblett , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Kevin Wilson
发明人: Christopher Hamblett , Dawn M. Mampreian , Joey L. Methot , Thomas Miller , David L. Sloman , Matthew G. Stanton , Kevin Wilson
IPC分类号: A61K31/496 , C07D401/04 , C07D241/36 , A61P35/00 , C07D409/14 , A61K31/497
CPC分类号: C07D213/56 , C07D239/28 , C07D401/12 , C07D487/08
摘要: The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
摘要翻译: 本发明涉及一类新型的取代烟酰胺。 这些化合物可以抑制组蛋白脱乙酰酶,适用于选择性诱导终末分化,阻止肿瘤细胞的细胞生长和/或细胞凋亡,从而抑制这些细胞的增殖。 因此,本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。 本发明的化合物还可用于预防和治疗TRX介导的疾病,例如自身免疫性,过敏性和炎性疾病,以及预防和/或治疗中枢神经系统(CNS)的疾病,例如 神经退行性疾病 本发明进一步提供包含本发明化合物和易于遵循的这些药物组合物的安全给药方案的药物组合物,并且其在体内导致治疗有效量的这些化合物。
-
-
-
-
-
-
-
-
-